Sucunamostat - SCOHIA PHARMA/Takeda
Alternative Names: SCO-792; TAK-792Latest Information Update: 28 May 2024
At a glance
- Originator Takeda
- Developer SCOHIA PHARMA; Takeda
- Class Acids; Amides; Amines; Antihyperglycaemics; Benzene derivatives; Benzofurans; Obesity therapies
- Mechanism of Action Enteropeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Obesity; Renal failure; Type 2 diabetes mellitus
- Phase I Homocystinuria; Maple syrup urine disease; Nephrotic syndrome; Phenylketonuria
- No development reported Diabetes mellitus; Diabetic nephropathies; Non-alcoholic steatohepatitis
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in Japan (PO)
- 18 May 2024 Pharmacodynamics data from the preclinical studies in Metabolic disorders presented at the Digestive Disease Week 2024 (DDW-2024)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in Japan (PO)